In the absence of any known cancer-associated mutations in the SphK isozymes or isoforms, the term “oncogenic addition”, where the cancer cell becomes reliant on SphK-S1P signaling for survival, has been proposed [86]. The gene discussed is MBTPS1; the disease is cancer.